arrow
P

Paul M. Armistead

university of north carolina medical center
H指数:27
被引数:2,515

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating day +90 donor chimerism as a prognostic marker of clinical outcomes among allogeneic hematopoietic cell transplant recipients who received myeloablative conditioning

评估第90天供者嵌合体作为接受骨髓清除性预处理的异基因造血细胞移植受者临床结局的预后标志物

2026-06-180
PRE
Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy

造血细胞移植或CAR T细胞治疗后对SARS-CoV-2疫苗接种的抗原特异性T细胞反应

2026-04-070
OAAI
Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults

CD30嵌合抗原受体T细胞疗法在成人中的感染并发症

2025-09-010
OA
A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing

一种他克莫司成人同种异基因造血细胞移植受者的群体药代动力学模型为精准给药提供了临床机会

2025-08-120
PRE
Azacitidine and Venetoclax with or without Donor Lymphocyte Infusion in Relapsed AML Post Allo-HSCT: A Single-Institution Retrospective Study

阿扎胞苷和维奈克拉,联合或不联合供者淋巴细胞输注,用于allo-HSCT后复发的AML:一项单中心回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
2024-05-277
PRE
Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses
2023-09-2555
PRE
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
2023-05-0116
OAAI
Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT
2023-04-268
OAAI
Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation
2021-07-017
OAAI